

## **Engagement Report for Clinical Commissioning Policies**

Unique Reference Number	1673
Policy Title	Infliximab for Progressive Pulmonary Sarcoidosis
Lead Commissioner	Kathy Blacker
Clinical Reference Group	A01 Specialised Respiratory
Which stakeholders were contacted to be involved in policy development?	Registered stakeholders of the Specialised Respiratory CRG and the Neurosciences CRG
	Sarcoidosis UK and British Lung Foundation nominated members who sat on the Policy Working Group
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	Royal College of Physicians and the British Thoracic Society are both members of the CRG as well as registered stakeholders of the CRGs. The Association of British Neurologists also responded.
Which stakeholders have actually been involved?	Registered stakeholders of the Specialised Respiratory CRG and the Neurosciences CRG. Eight responses were received in total.
Explain reason if there is any difference from previous question	
Identify any particular stakeholder organisations	N/A

that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?	
How have stakeholders been involved? What engagement methods have been used?	Members from CRG and patient organisations are on the PWG. Stakeholder engagement process. 14 day email engagement exercise with registered stakeholders
What has happened or changed as a result of their input?	Clarification that the policy refers to the use of Infliximab in Progressive Pulmonary Sarcoidosis and the title and wording have been altered to reflect this. The Neurosciences CRG have decided to support a separate Preliminary Policy Proposition for the use of Infliximab in Neurological Sarcoidosis.
How are stakeholders being kept informed of progress with policy development as a result of their input?	Stakeholders will be kept informed of the policy's progress through NHS England's consultation portal website
What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?	Not all stakeholders made a recommendation. Of those that did selected 3 supported option 1 and 3 supported option 2.  1 - changes that could reasonably be expected to be broadly supported by stakeholders - up to 6 week consultation 2 - up to 12 weeks consultation to include some additional proactive engagement activities during the live consultation period.  We believe that following the amendments made a 4 week consultation period will be sufficient and that no proactive engagement activities will be required.